Attendance an online digital event on Dec. 09, 2024 entitled “Artificial Intelligence in Drug Development and Clinical Trials”. The event was offered by International Pharmaceutical Federation (FIP).

Description: The webinar outlined how disruptive technologies and innovative concepts transformed the design and execution of clinical trials. These advancements signified that sponsors and all trial stakeholders, including sites and technology partners, needed to adapt to meet the demands of this evolving paradigm.

In this session, Dr. Kubassova discussed the core elements of a digital strategy essential for integrating novel technologies into clinical trials. She also highlighted the importance of a data-driven approach to drug development and examined how incorporating AI into the drug development process influenced costs, speed, and the overall success of pharmaceutical innovation. These principles were presented as applicable to developing drugs for specific indications or conducting real-world evidence studies.

Chair: 

- Mathew Cherian, VP of Operations & Development, ReVive Biotechnology, United States.

Co-moderator:

- Nikolina Biskic, Regulatory Affairs Manager, Switzerland.

Panellist:

- Olga Kubassova, Founder and President of Image Analysis Group, UK.